Author: Leaker, Brian R.; Singh, Dave; Lindgren, Sam; Almqvist, Gun; Eriksson, Leif; Young, Barbara; O’Connor, Brian
Title: Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study Document date: 2019_12_19
ID: 15e043uf_53
Snippet: AZD8848, administered once-weekly during an 8week treatment period was generally well tolerated. As reported in other clinical studies, [24] symptoms possibly linked to activation of the IFNα pathway were more prevalent after administration of AZD8848 compared with placebo, but these were generally mild in intensity. Increased nasal side effects have previously been reported with AZD8848 treatment, notably at doses of 100 μg and above, [24] or .....
Document: AZD8848, administered once-weekly during an 8week treatment period was generally well tolerated. As reported in other clinical studies, [24] symptoms possibly linked to activation of the IFNα pathway were more prevalent after administration of AZD8848 compared with placebo, but these were generally mild in intensity. Increased nasal side effects have previously been reported with AZD8848 treatment, notably at doses of 100 μg and above, [24] or with more frequent dosing [27] . In the present study, at the lower dose of 60 μg once-weekly, the overall incidence of nasal symptoms was similar in the active and placebo-treated groups and the incidence of mucosal ulceration was limited to a single individual in the active treatment group.
Search related documents:
Co phrase search for related documents- low dose and placebo treat: 1
- nasal effect and present study: 1, 2
- nasal effect and treatment group: 1, 2, 3, 4, 5
- nasal effect and treatment period: 1
- nasal symptom and overall incidence: 1, 2
- nasal symptom and present study: 1, 2, 3
- nasal symptom and treatment group: 1
- nasal symptom and treatment period: 1
- overall incidence and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- overall incidence and single individual: 1, 2
- overall incidence and treatment group: 1, 2, 3, 4, 5, 6
- overall incidence and treatment period: 1, 2
- placebo compare and treatment group: 1
- placebo treat and present study: 1
- present study and single individual: 1, 2
- present study and treatment group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- present study and treatment period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- single individual and treatment group: 1, 2, 3, 4
- single individual and treatment period: 1
Co phrase search for related documents, hyperlinks ordered by date